The skin represents an excellent site for vaccine inoculation due to its natural role as a first line of contact with foreign pathogens and the high local frequency of antigen presenting cells. To facilitate skin-directed immunization, a new technique has been developed (termed microporation) whereby a vaporization process is used to remove tiny areas of the stratum corneum creating microscopic pores that allow access to the underlying viable epidermis. Reporter gene expression was 100-fold increased following application of an adenovirus vector to microporated skin when compared to intact skin. Furthermore, 10-100-fold greater cellular and humoral immune responses were observed following topical administration of an adenovirus vaccine to microporated skin versus intact skin. Hairless mice responded to the microporated adenovirus vaccine equivalently to mice with normal hair follicle distribution demonstrating the activity of the microporated vaccine was not related to follicle count. In a tumor challenge model using a surrogate antigen, microporation increased vaccine efficacy by approximately 100-fold compared to intact skin. Finally, microporation enabled delivery of an adenovirus vaccine carrying a relevant melanoma antigen resulting in the development of autoimmune vitiligo and tumor protection. Thus, the microporation technology has proven to be a reliable and easy method to enable skin-directed vaccination.
Introduction
Our skin is an extremely relevant tissue with respect to immune defense since we are continually exposed to foreign pathogens at this site through cuts and abrasions. The high density of antigen presenting cells (APC) in the skin, known as Langerhans cells, supports the theory that the skin is a major site of immune initiation. 1 Thus, immunization at the skin is likely to be more effective and more relevant than vaccination via the subcutaneous, intramuscular or parenteral routes. Indeed, several recent publications investigating genetic vaccines have demonstrated that the intradermal route of administration yielded the highest efficacy. [2] [3] [4] However, efficient intradermal injection is both difficult and painful and is hampered by the short depth of the skin limiting the volume of the inoculum and, quite often, the payload is delivered to the subcutaneous region rather than the dermis.
Microporation has been developed to increase the permeability of the skin to facilitate the transdermal infusion of drugs and vaccines, as well as enable the extraction of interstitial fluid from the skin for diagnostic purposes. 5 For skin immunization, the microporation technique involves the creation of an array of physical openings through the stratum corneum into the viable epidermis to allow direct contact between the cells of the epidermis and the vaccine inoculum. These openings are large enough to allow the delivery of macromolecules such as protein antigens, DNA or even microparticles into the epidermis. A simple inexpensive way to perform microporation is to apply an array of tiny resistive elements to the skin surface and pass a short duration electrical current (milliseconds) through the array. As a result of resistive heating, the cells of the stratum corneum that are in contact with the elements are vaporized, leaving a microscopic hole (micropore) in the stratum corneum. In contrast to the creation of pores with other enhancement techniques, such as electroporation, microporation involves a physical removal of cells. However, these openings are formed temporarily, since the layers of the stratum corneum are continuously being replaced through the natural process of desquamation. By removing the stratum corneum, the permeability of the skin is increased dramatically, since the stratum corneum is responsible for providing the skin's barrier to permeation by external agents. 6 The dimensions of the micropores can be precisely controlled to a given size (area and depth) and shape by selecting the appropriate microporation parameters and resistive element geometry. Penetration of the resistive element into the outer layers of the skin is physically limited by the substrate they are attached to and the thermal vaporization process occurs so rapidly that the high temperatures required for vaporization do not penetrate into the lower epidermis. Since the temperature gradient does not reach the capillary loops or pain-sensing nerves in the upper dermis, the process is pain-free and non-traumatic. Other devices that are being developed to deliver vaccines to the epidermis include, ballistic particle delivery ('gene gun'), microprojections, electroporation and liquid jet injectors. [7] [8] [9] [10] There are no clear criteria at this point to identify the optimal device for epidermal delivery, however, the flexibility, reproducibility, and ease of use of the microporation technology makes it highly attractive for this application.
We are investigating microporation as a tool for genetic immunization using replication-defective adenoviruses (rdAds) as prototype vaccines. 2, 11 RdAds exhibit a number of properties that make them appealing vectors for genetic vaccination: (1) they elicit robust cellular and humoral responses, (2) they can readily accommodate up to 8 kb of foreign DNA, (3) they are easily manipulated and propagated using basic molecular biology and tissue culture techniques and (4) they have not been associated with disease in immunocompetent hosts. 12 Despite the high efficacy of rdAd vaccines delivered intradermally, 2, 3 reproducibly delivering materials to the skin using a standard needle and syringe is technically challenging. Topical administration should prove less complicated and, indeed, previous reports have demonstrated that rdAds can successfully immunize mice following topical application to de-cornified skin. [13] [14] [15] Removal of the cornified skin layer involved user-specific methods such as depilatories, soft brushing and adhesives. We expect microporation to provide a standardized, painless method to prepare the skin for topical delivery of rdAds. In the following manuscript, we demonstrate that microporation enhances the efficiency of rdAd vaccines following topical delivery proving this technique to be a useful and painless needle-free method for genetic vaccine delivery.
Results
Increased gene expression following topical application to microporated skin Figure 1a is a schematic representation of a micropore array. Essentially, a 10 Â 12 array of pores is created on the mouse abdomen. Since these pores are on the order of 100 mm in size, they are not obvious to the naked eye. Figure 1b is a surface view of a single micropore at 200 Â magnification.
To determine whether microporation would increase the delivery of Ad vectors to the skin, AdLuc was applied to both intact skin and microporated skin. Twenty-four hours later, the site of inoculation was removed and processed to measure luciferase gene expression. Similar levels of gene expression were observed in BALB/c, B6/129 and C57Bl/6 demonstrating the reproducibility of this technique (Figure 2 ). Application of AdLuc to microporated skin resulted in a 100-300-fold increase in luciferase activity compared to intact skin controls (Figure 2 ; compare black bars to gray bars).
Previous reports have suggested that gene transfer agents access the skin via hair follicles following topical application, 13 therefore, the enhanced gene transfer across microporated skin may be a unique feature of the high follicle density of murine skin (approx. 660 follicles/cm 2 ). To address this possibility, the experiment was repeated using SKH-1 hairless mice which are immune-competent and exhibit a hair follicle frequency (approx. 75 follicles/cm 2 ) closer to human skin (approx. 10 follicles/cm 2 ). 16 Despite a 10-fold difference in hair follicle density, we observed similar levels of gene expression following microporation of hairless mice, which demonstrates that gene transfer to the skin through micropores was not hair follicle dependent.
Interestingly, gene expression following application of AdLuc to intact skin of hairless mice was reduced compared to B6/129 and C57Bl/6 mice (2.5-fold) consistent with the hypothesis that gene transfer across intact skin is mediated by hair follicles, although this difference was not statistically significant (P¼0.327).
Microporation increases the activity of rdAd vaccines
BALB/c mice were immunized with a solution of Adbgal (5 Â 10 6 pfu/ml) topically applied to both intact and microporated skin. Fourteen days later, the cellular and humoral responses were measured. In two separate experiments, only two of seven mice exhibited CTL reactivity following application of the virus to intact skin, whereas 100% of the microporated mice were positive for CTL activity ( With respect to humoral responses, application of the Adb-gal vaccine to microporated skin resulted in 100% seroconversion (13 mice), whereas antibodies to b-gal were only measurable in 3/13 mice immunized by application of the vaccine to intact skin ( Figure 4) . Interestingly, application of the vector to microporated skin produce a mixed response (type 1 and type 2; ie IgG1DIgG2a) as determined by anti-b-gal isotype. This is in contrast to the results we obtained when the Adbgal was administered intramuscularly where the response was mainly of type 1 (ie IgG2a44IgG1; J Bramson, unpublished data).
To gain further insight into the enhancement of topical Adb-gal immunization via microporation, the vaccination procedure was repeated with lower doses of Adb-gal (5 Â 10 5 and 5 Â 10 4 pfu/ml) ( Table 1) . Within the intact skin group, antibodies were only measurable in 1/8 mice following immunization with the intermediate load of virus (5 Â 10 5 pfu/ml) and no antibodies were detectable in mice vaccinated with the lowest dose (5 Â 10 4 pfu/ml). In contrast, antibodies were detectable in nearly 100% of mice (7/8) immunized with the medium load of virus following microporation and a response was measurable in 1/8 mice vaccinated with the lowest dose. Thus, in terms of the humoral responses, microporation can enhance the efficacy of Adb-gal immunization by at least 10-fold in BALB/c mice.
Role of hair follicles
SKH-1 hairless mice were similarly immunized with the high dose of Adb-gal (5 Â 10 6 pfu/ml) topically applied to intact and microporated skin. These mice are outbred making it difficult to analyze CTL responses; therefore, cellular responses were measured by IFN-g ELISPOT using recombinant b-gal protein as stimulus. Interestingly, the hairless mice were more responsive than hairy BALB/c mice following application of the vaccine to intact skin ( Figure 5 ). There was an overall three-fold increased cellular response in the microporated group, as measured by ELISPOT [301733 SFC (microporation) Microporation greatly enhances gene transfer to the skin. AdLuc (5 Â 10 6 pfu/ml) was applied to both microporated skin and intact skin. Twenty-four hours later, the skin was removed and processed for luciferase measurement. Each bar represents the mean RLU/mouse +s.e.m. of three to four mice per group. Figure 5a ] with 6/6 microporated mice responding to the vaccine but only 5/6 mice in the intact skin group. Similarly, 6/6 mice were positive for b-gal antibodies following microporation, while only 4/6 mice seroconverted following application of the vaccine to intact skin ( Figure 5b ). Thus, the activity of microporated rdAd vaccines does not appear to be dependent upon hair follicles.
Enhanced anti-tumor immune responses following application of Adb-gal to microporated skin
Protection from tumor challenge is a more relevant measurement of vaccine activity. Therefore, we evaluated the ability of the microporated Adb-gal vaccine to protect BALB/c mice from challenge with the CT-26.CL25 tumor, which expresses b-gal as a surrogate antigen. In this model, microporation resulted in a substantial enhancement of vaccine activity. Mice receiving microporated vaccine exhibited some degree of protection from tumor challenge at all the vaccine doses (5 Â 10 6 , 5 Â 10 5 and 5 Â 10 4 pfu/ml) whereas mice immunized via intact skin only displayed weak protective responses, even at the highest dose ( Figure  6 ). In fact, the microporated groups were virtually 100% protected at both the 5 Â 10 6 and 5 Â 10 5 pfu/ml doses. Furthermore, the highest dose of vaccine (5 Â 10 6 pfu/ml) applied to intact skin only achieved 27% protection from lung metastases which was comparable to the 38% protection achieved following application of the lowest vaccine dose (5 Â 10 4 pfu/ml) to microporated skin. Therefore, based on the tumor protection data, microporation can increase the potency of the Adb-gal immunization by 100-fold. Immunization with AdLuc (5 Â 10 6 pfu/ml) applied to microporated skin failed to elicit protective immunity confirming that the response was antigen-specific (data not shown).
Microporation can increase the activity of rdAd vaccines expressing weak immunogens
We have observed previously that the activity of genetic vaccines (RdAd and plasmid DNA) is partially dependent upon the antigen. 17 In our experience, b-gal is a robust antigen, which leads to strong responses, while chicken egg ovalbumin (OVA) is a weaker immunogen (J Bramson, unpublished results). Since microporation only produced a modest increase in vaccine efficacy in hairless mice as compared to delivery on intact skin, we sought to determine if the impact of microporation would be more obvious following vaccination with a weaker antigen. Hairless mice were immunized with a comparable rdAd vector expressing OVA (AdOVA) at a dose of 5 Â 10 6 pfu/ml applied to intact or microporated skin. Again, 100% of microporated mice exhibited a cellular response against OVA as measured by ELISPOT, by contrast, no reactivity was observed in the intact skin group (Figure 7a ). Similarly, 6/6 microporated mice developed OVA antibodies, compared to 2/6 mice in the intact skin group (Figure 7b) . Thus, microporation does not only increase the efficacy of the vaccine inoculum, it can also increase the immunogenicity.
Application of AdhTRP-2 to microporated skin leads to auto-immune vitiligo and protection from melanoma challenge Many melanoma antigens have been identified over the past decade, several of which are non-mutated proteins associated with melanin synthesis. One antigen, TRP-2, has displayed promising activity in pre-clinical models. 3, 18, 19 AdhTRP-2 (5 Â 10 6 pfu/ml) was applied two times to either intact or microporated skin 21 days apart followed by a challenge with B16 Figure 4 Increased magnitude and rate of seroconversion following topical administration of genetic vaccine to microporated skin. Adb-gal (5 Â 10 6 pfu/ml) was applied to both microporated and intact skin. Fourteen days later, antibodies were measured in the serum. Each line represents the mean OD 7s.e.m. for 13 mice. Closed symbols, microporated skin; open symbols, intact skin; bracketed numbers, fraction of mice which were sero-positive for b-gal antibodies. Enabling topical vaccines by microporation J Bramson et al resulted in long-term protection from tumor growth (3/6 mice protected from tumor growth at day 40 compared to 1/8 mice in the intact skin group) and, in addition, 1/6 mice were completely protected from tumor growth (Figure 8a) .
Effective immunization against TRP-2 has been correlated with auto-immune reactivity towards normal melanocytes resulting in de-pigmentation of the skin (vitiligo). [18] [19] [20] Vitiligo has been associated with other melanoma vaccines and may be an unavoidable consequence of effective tumor immunity. 21, 22 Interestingly, 13/13 mice vaccinated by application of AdhTRP-2 to microporated skin developed vitiligo at the site of inoculation within 2 weeks following immunization (Figure 9a ) whereas no vitiligo was observed following application of AdLuc (0/8) (data not shown). By comparison, no mice immunized by application of AdhTRP-2 to intact skin developed vitiligo (0/8; Figure  9b ).
Discussion
The results of these studies clearly demonstrate the effectiveness of the microporation technology for enhancing topical application of rdAd vectors in two settings: (1) gene transfer to the skin and (2) genetic immunization. We observed that microporation could enhance the activity of rdAds by up to 100-fold, supporting further investigation of this technology. While vector administration was accomplished using passive delivery in these experiments, we are currently developing enhancing technologies (eg ultrasound and electroporation) to increase the delivery of materials through the micropores and into the tissue. Preliminary time course experiments with passive microporation patch application determined that a 2-h exposure to the vaccine patch can elicit similar, albeit slightly decreased, immune responses as an 18-h exposure (unpublished results). Thus, we expect that the active delivery process will not only increase the efficacy of delivery but also reduce the required exposure time. Our design should also provide great flexibility in terms of the material that can be administered since no special formulations or carriers are required. In theory, any inoculum (liquid or solid) that can be embedded into a patch can be placed upon the microporated area.
We cannot determine with certainty the volume of the inocula that is presented to the micropores but we estimate that it is less than 2 ml based on pore size and depth and the number of pores that are actually exposed to the vaccine preparation. According to this approximation, we are exposing mice to 1 Â 10 7 pfu rdAd following application of the highest vaccine dose. In a study where the rdAd vaccine was applied to skin that was decornified by gentle brushing, 15 seroconversion occurred at doses of 10 8 particles (approx. 10 6 pfu) and high-level protection from challenge (480%) required at least 10 9 Figure 7 Microporation can greatly enhance the immunogenicity of adenovirus vaccines carrying weak antigens. AdOVA (5 Â 10 6 pfu/ml) was applied to both microporated and intact skin of hairless mice. Twenty-one days later, spleens were harvested for ELISPOT analysis with purified, recombinant protein and anti-OVA antibodies were measured in the serum. Results represent the mean OD 7s.e.m. for six mice. Enabling topical vaccines by microporation J Bramson et al particles (approx. 10 7 pfu), quite similar to our observations with Adb-gal. Thus, despite differences in antigen and challenge models, microporation appears to produce comparable results as other de-cornification procedures. A potential advantage of microporation in this setting is that it offers a controllable and reproducible technology for topical delivery of rdAds, supported by our results demonstrating similar levels of gene expression following application of AdLuc to skin in four mouse strains (BALB/c, C57Bl/6, B6/129 and hairless). With respect to clinical application, a method which can be standardized (microporation) might be preferable than one which is user specific (de-cornification with a brush).
We were also able to generate protective anti-tumor immunity and auto-immune vitiligo using one or two administrations of 1 Â 10 7 pfu rdAd in the CT-26.CL25 and B16 tumor models, respectively, consistent with previous reports where doses generally ranged between 10 8 and 10 9 pfu per immunization. 3, 18, [23] [24] [25] Thus, with our current passive approach we can employ similar virus doses as those using intradermal and subcutaneous routes. We expect that the active delivery methods that we are developing will further increase the potency of the microporation technology.
Presently, we are unable to compare the efficacy of microporation to other epidermal-delivery technologies since we employed rdAd for our studies whereas the other methods have used either protein or plasmidbased vaccination. Using a simple patch/skin-hydration approach, Glenn et al have demonstrated that effective immunity against protein antigens can be elicited by formulating the vaccine with a bacterial toxin. 26, 27 Whether or not the hydration technology will influence genetic vaccines remains to be determined. Gene-gun delivery, which requires that the vaccine inoculum be precipitated onto gold beads, was initially thought to be restricted to plasmid vaccines due to formulation issues. However, protein-based and conventional flu vaccines have recently been formulated for gene-gun mediated delivery resulting in CTL responses which are not normally produced by standard inoculation of these vaccines. 8, 28 Whether or not live vaccines (eg rdAd) can Figure 8 Growth of B16 tumors following immunization with AdhTRP-2 applied to microporated skin. AdhgTRP-2 (5 Â 10 6 pfu/ml) was applied to both microporated and intact skin of C57Bl/6 mice two times, 21 days apart. Fourteen days later, all mice were challenged with 2 Â 10 4 B16F10 cells subcutaneously. Panel (a) microporated skin; panel (b) intact skin; and panel (c) non-immune control mice.
Enabling topical vaccines by microporation J Bramson et al be formulated for gene-gun delivery requires further investigation. The microprojection technologies should be able to deliver rdAd either by coating the projections with virus or delivering fluid through a liquid reservoir associated with the projections. 6 In summary, our results have proven the utility of the microporation technology for the delivery of genetic vaccines. We are advancing the results provided in this manuscript by characterizing the mechanisms of immunization (eg transduction of Langerhans cells, involvement of skin versus lymphoid tissue, etc) and evaluating other vector systems (plasmid DNA and ex vivo autologous dendritic cells).
Materials and methods
Mice BALB/c, C57Bl/6 and SKH-1 hairless mice were obtained from Charles River. B6/129 are an F1 cross between C57Bl/6 and 129/Sv generated at McMaster. All mice were maintained in level B housing (autoclaved cages with microisolator lids; all manipulations carried in biological safety cabinets) throughout the course of the experiment.
Replication-defective adenovirus (rdAd) vectors
All rdAd vectors used in this manuscript were deleted for both the E1 and E3 regions and constructed using a recently developed, high-efficiency system for virus rescue. 29 Transgene expression cassettes were inserted into the E1 region under the control of the murine cytomegalovirus promoter. Adb-gal expresses Escherichia coli b-gal, AdOVA expresses chicken egg ovalbumin (OVA) and AdhTRP-2 expresses the melanoma antigen, TRP-2. Viruses were propagated using 293 cells and purified by CsCl gradient centrifugation as described previously. 30 
Cell culture
Plasticware used for cell culture was purchased from Falcon. Most cells (including splenocytes) were cultured in cRPMI consisting of RPMI 1640 supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 50 mM bmercaptoethanol, 100 U/ml penicillin and 100 mg/ml streptomycin. SOBalb is a lung fibroblast line that was isolated from a BALB/c mouse. CT-26.CL25 cells that express b-gal were maintained in cRPMI containing 400 mg/ml G418. The B16F10 murine melanoma cells were cultured in Dulbecco's Modified Eagle's Medium containing the same supplements as cRPMI. Peptides used for CTL activation were synthesized at the William K Warren Medical Research Inst. (University of Oklahoma, USA) and dissolved in water at a final concentration of 10 mg/ml.
Luciferase assays
Tissues were harvested from mice and immediately snap-frozen in liquid nitrogen. Frozen tissues were placed in 1 Â cell culture lysis reagent (Promega) and homogenized using a polytron (Kinematica). Debris was cleared from the homogenate by a 10 min centrifugation at 3000 rpm. Luciferase activity was then measured using the Luciferase Assay kit (Promega) and a Tropix TR-717 microplate luminometer according to the directions provided by the supplier.
Microporation
A prototype microporation system (Altea) was used to create an array of microscopic pores in the stratum corneum of the mouse abdomen. Each tiny spot of stratum corneum was removed by the application of focused thermal energy based on resistive heating via the contact of a electrically heated small-diameter wire to the skin surface. The prototype system included a laptop computer, microprocessor control circuitry, a three-axis Enabling topical vaccines by microporation J Bramson et al stepper motor assembly with microporation tip holder, and an animal interface plate compatible with various small animal models. The microporation tip was comprised of a set of 80 mm diameter tungsten wires strapped over the edge of a ceramic substrate and electrically connected to the control circuitry via copper traces on each side of the substrate. The control circuitry allowed for the precise control of the electrical current pulses that were passed through each wire. The software user interface was designed to enable the control of various microporation parameters including micropore density, resistive element temperature, current pulse width, number of pulses, pulse spacing, and contact pressure. The temperature of the tip that was placed in contact with the skin was calibrated with the use of an optical calibrator device. The microporation parameters were the same for all three types of mice that were studied: BALB/c, C57/Bl6, B6/129, and SKH-1 hairless mice. The prototype microporation system parameters were set to create an array of micropores with a pore density of 75 micropores/cm 2 , each measuring approximately 80 mm wide, 300 mm long and 40-50 mm in depth, as determined by microscopy.
Mice were anesthetized and their abdominal hair was closely trimmed using an electric trimmer (no scraping of the skin surface). After trimming, the skin was inspected to ensure that it was intact and was then wiped clean with alcohol and lightly dried with a lint-free tissue. The mouse was then placed on the animal interface plate with the abdomen facing down and positioned over an opening to allow access to the microporation tip assembly. A square array of micropores was then created sequentially in a step and repeat fashion (see Figure 1a) .
Liquid reservoir patch
After the microporation process was complete, the mouse was placed on the benchtop with the abdomen facing up. Then, a liquid reservoir patch shaped like a donut, with a 1 cm inside diameter and 25 mm outside diameter, was applied over the micropore array. The volume of liquid that was contained by the liquid reservoir patch was determined by the thickness of the patch. Depending on the experiment, two different patch volumes were utilized (25 ml and 90 ml) with identical results. With the circular patch in position over the micropore array (75 micropores/cm 2 ), approximately 60 micropores were exposed to the vaccine inoculum. The liquid reservoir patch was designed to allow for in situ filling of the rdAd solution using a 27 G insulin needle without the introduction of trapped air or air bubbles. After filling, the patch was sealed with an adhesive film and further secured to the skin with a Tegaderm (3 M) dressing. The patch was left in position for 24 h and then removed. During the 24 h, the patch was closely monitored to ensure that there were no leaks or air bubbles, and that the patch remained intact in its original position.
Immunizations
RdAds were diluted to 5 Â 10 6 , 5 Â 10 5 or 5 Â 10 4 pfu/ml in PBS and applied to shaved abdomens (either intact or microporated) using patches with either a 25 or 90 ml fluid reservoir. The patches were secured using Tegaderm (3 M) and removed the following day. Upon removal of the patch, the murine abdomen was washed to remove residual virus.
ELISPOT assays
Prior to loading test samples, Millipore Multiscreen-IP plates were coated overnight at 41C with 100 ml/well of the IFN-g capture antibody, R4-6A2 (Pharmingen), diluted to 10 mg/ml in PBS. Unbound antibody was removed by three consecutive washes with 150 ml/well PBS. To block non-specific binding sites, cRPMI was added (150 ml/well) and the plates were incubated at 371C for a minimum of 2 h. The test samples were then added in duplicate at 6 Â 10 5 and 1.2 Â 10 5 cells/well in 50 ml cRPMI. To measure anti-b-gal reactivity, we added TPHPARIGL peptide at a final concentration of 2 mg/ml or whole b-gal protein at a final concentration of 50 mg/ ml. To measure anti-OVA reactivity, we added whole OVA protein to a final concentration of 50 mg/ml. As a negative control, each test sample was stimulated with an irrelevant peptide or protein antigen. After a 24-h incubation at 371C, the wells were washed 6 times with PBS/0.05% Tween-20. Biotinylated-detection antibody, XMG1.2 (Pharmingen), was then added (2 mg/ml in PBS/0.5% BSA; 100 ml/well) and the plates were incubated for 2 h at 371C. The wells were washed 6 times with PBS/0.05% Tween-20 and the spots were developed using the ELISPOT blue color module from R&D Systems according to the manufacturer's instruction. To calculate the number of antigen-specific SFCs, the number of spots in the negative control wells were subtracted from the number of spots in the specific antigen-stimulated wells and normalized to 10 6 splenocytes.
Chromium (
51 Cr)-release assays
51
Cr-release assays were performed as previously described. 31 . Splenocytes were isolated from immunized mice and CTL precursors and re-stimulated by the addition of TPHPARIGL peptide at a final concentration of 2 mg/ml. Five days later, the re-stimulated splenocytes (ie effectors) were diluted into 96-well plates and cocultured in parallel with either 10 4 Na 51 CrO 4 -labeled SOBalb or TPHPARIGL-pulsed SOBalb for 4-6 h.
Cr released into the medium was measured using a TopCountNX microscintillation counter (Packard).
Antibody ELISA
Serum was harvested from mice by cardiac puncture 14 days after immunization. Maxisorp ELISA plates (Nunc) were coated with b-gal or OVA antigen (10 mg/ml in coating buffer) or adenovirus lysate (100 mg/ml in PBS) at 41C overnight. The wells were washed [wash buffer¼PBS+0.01% Tween-20] to remove unbound antigen and incubated with blocking buffer [wash buffer+1% BSA] to prevent non-specific antibody binding. Sera were serially diluted [dilution buffer¼wash buffer+0.3% BSA], added to the plate and incubated for 2 h at 371C. The wells were washed again and IgG subclasses were detected using biotinylated anti-mouse IgG1 or IgG2a (Southern Biotech Associates), followed by steptavidinlinked alkaline phosphatase (Zymed) and p-nitrophenyl phosphate (Sigma) was used as a colorimetric substrate.
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Tumor challenge studies CT-26.CL25:. Fourteen days following immunization, mice were inoculated with 10 5 CT-26.CL25 cells intravenously. Fourteen days later, lungs were harvested and washed several times in PBS. To enumerate lung metastases, the lungs were fixed in 2% formaldehyde, 0.2% paraformaldehyde, 0.02% NP-40, 0.01% Na deoxycholate at 41C for 1 h. Excess fixative was removed by several washes in PBS and the lungs were stained in 5 mM K 3 Fe(CN) 6 , 5 mM K 4 Fe(CN) 6 , 2 mM MgCl 2 , 0.1% Xgal overnight at room temperature. X-gal stain was removed the following day, the tissues were fixed again in formaldehyde solution and stored in methanol at 41C. Lung metastases were scored using a dissecting microscope and scored up to 100 nodules.
B16F10: Fourteen days following the final immunization with AdhTRP-2, mice were inoculated with 2 Â 10 4 B16F10 cells subcutaneously. Tumor formation was monitored over a period of 28 days. Tumor volume was calculated using the following formula: (L ÂW Â H)p/2. Animals were euthanized when the tumors measured greater than 20 mm in one dimension or greater than 10 mm in two dimensions.
